|Audit||Nominating and Governance||Compensation||Strategic|
|John T. Henderson, M.D.|
|Lawrence C. Best|
|Heiner Dreismann, Ph.D.|
|Walter Gilbert, Ph.D.|
|Dennis Langer, M.D, J.D.|
Managing Partner, Phoenix IP Ventures
Dennis Langer, M.D., J.D. is a Director of the Company as of May 2004. He was previously Senior Vice President in Research and Development at GlaxoSmithKline and has a broad base of experience in innovative R&D companies such as Eli Lilly, Abbott and GD Searle. He is also a Clinical Professor at the Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer has earned a J.D. (cum laude) from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University.
|S. Louise Phanstiel|
Stock transaction information provided by EDGAR Online. Myriad Genetics, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
Stock Quote (NASDAQ:MYGN)
Provided by eSignal.
Corporate Communications and Media Relations